ResMed stock
Price history
−1.45% over the period1 year: from $244.71 (November 17, 2025) to $241.16 (November 16, 2026), −1.45%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $241.16 |
| October 30, 2026 | $229.94 |
| September 30, 2026 | $221.10 |
| August 31, 2026 | $240.10 |
| July 31, 2026 | $210.98 |
| June 30, 2026 | $194.88 |
| May 29, 2026 | $190.57 |
| April 30, 2026 | $213.81 |
| March 31, 2026 | $224.48 |
| February 27, 2026 | $256.26 |
| January 30, 2026 | $258.31 |
| December 31, 2025 | $240.87 |
| November 28, 2025 | $255.83 |
| November 17, 2025 | $244.71 |
At a glance
The company
Develops digital health and cloud-connected medical devices for sleep and breathing health, plus software for residential care providers
Latest results
Quarter to September 30, 2026 · EPS $2.91 (estimate $2.68)
Next event
TickerLandia's take on ResMed
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 38 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 22 vs 34 (−36%) in a group of 9.
- Strong point: Profitability (85/100 in its group). Weak point: Dividend (36/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−13.15% from the 52-week high
Analysts · 20 analysts
Average target$264.33+9.61% vs. price
Buy 9 · Hold 10 · Sell 1 · Buy
TickerLandia Fingerprint: ResMed
Compared with similar companies: very high profitability and very high financial strength.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage47
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 21.8 18 EV/EBITDA 15.7 46 Forward P/E 18.1 37 Price/book 5.66 66 Price/sales 5.88 66 Profitabilityvery high85
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 34.0% 91 Gross margin 61.8% 68 Net margin 27.8% 91 ROE 26.4% 85 ROA 14.8% 91 Earnings stabilityaverage54
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.0% 46 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage58
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.21% 79 Earnings growth (year over year) +23.20% 45 Revenue growth (year over year) +5.90% 50 Financial strengthvery high80
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.10 85 Current ratio 2.65 79 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.31 76 Dividendlow36
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 15 years 38 Payout ratio 23.0% 23 Dividend yield 1.1% 46 Market momentumaverage58
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +16.52% 74 1-year return −4.99% 24 Relative strength (3 months) +8.96% 72 Distance from 200-day average +6.99% 60 Riskaverage48
How much the price swings.
Metric Value Position in group Volatility (60 days) 31.5% 43 Beta (1 year) 0.50 41 Maximum drawdown (12 months) 33.8% 62
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ResMed is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), ResMed's P/E today is 23.1, below the median of its last 10 fiscal years (37.7; between 18.7 and 76.1 from 2017 to 2026). ResMed's P/E (trailing 12 months): 21.8, −36% against the median of a group of 9 similar companies (34.2).
Compared with 9 similar companies
| Metric | ResMed | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.8 | Low | |
| Forward P/E | 18.1 | Middle | |
| Operating margin | 34.0% | High | |
| ROE | 26.4% | High | |
| Debt/equity | 0.10 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ResMed. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.46B
Latest quarter · Q2 2026
Net income
$383.43M
Latest quarter · Q2 2026
Quarterly net margin
26.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $33.69B
- P/E
- 21.8
- EPS
- $10.98
- Volume
- 836.36K
- Daily trading
- €309.48M
- Dividend yield
- 1.04%
- Last ex-dividend on November 12, 2026
How ResMed is changing
All resultsRevenue grew 12.1% a year on average over the last 5 years
Operating margin rose from 26.8% to 33.4%
Profits turn into cash: free cash flow equal to 117% of net income
Returns
ResMed returns with dividends
$1,000 invested in ResMed 5 years ago, on November 16, 2021, would be worth $948 today with dividends reinvested: −5.16% in total, −1.05% per year. On price alone it would be $905 (−9.50%).
| Period | ResMed | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +0.91% | −3.12% | $1,009 |
| 6 months | +19.45% | +2.07% | $1,195 |
| Year to date | +0.12% | +10.46% | $1,001 |
| 1 year | −0.36% | +13.33% | $996 |
| 3 years | +66.76% | +67.73% | $1,668 |
| 5 years | −5.16% | +60.86% | $948 |
| 10 years | +365.29% | +247.35% | $4,653 |
Over the last 6 months it has done better than 52% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
ResMed: technical analysis
ResMed shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 18.9% below its all-time closing high ($297.36, September 8, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- +7.76%
Support and resistance
Price areas where ResMed has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$263.48+9.26%2 touches, last on January 22, 2026
- Resistance$258.47+7.18%4 touches, last on October 23, 2026
- Resistance$245.43+1.77%2 touches, last on February 12, 2026
- Last price$241.16
- Support$240.70−0.19%5 touches, last on September 1, 2026
- Support$233.95−2.99%3 touches, last on September 15, 2026
- Support$222.01−7.94%2 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.50
- Volatility (60 sessions, annualised)
- 31.4%
- Largest fall in the last year
- −33.75%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ResMed: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for ResMed has been November: +5.62% on average, positive in 25 years out of 31. The weakest has been October: −0.30% on average, positive in 13 years out of 32.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.52% | +5.33% | 22 of 31 |
| February | +0.23% | +0.35% | 16 of 31 |
| March | +1.27% | +1.52% | 18 of 31 |
| April | +1.43% | +2.23% | 17 of 31 |
| May | +0.91% | +1.75% | 19 of 31 |
| June | +3.81% | +3.03% | 21 of 31 |
| July | +3.13% | +3.01% | 24 of 32 |
| August | +3.12% | +2.39% | 20 of 32 |
| September | +1.26% | −0.77% | 12 of 32 |
| October | −0.30% | −1.30% | 13 of 32 |
| November | +5.62% | +3.40% | 25 of 31 |
| December | +1.81% | +1.41% | 18 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ResMed and its competitors
Founded in 1989 and based in San Diego, California, ResMed develops digital health and cloud-connected medical devices, with a focus on sleep apnea. Its sleep recorders, such as ApneaLink Air and NightOwl, are used in sleep clinics, hospitals and at home, while AirView and the myAir application allow remote monitoring of device settings and patient therapy. Through its Residential Care Software segment, the company supplies software to home medical equipment and pharmacy providers, home health and hospice agencies, and skilled nursing and senior living operators, including Brightree, HEALTHCAREfirst, MatrixCare and MEDIFOX DAN.
- Headquarters
- San Diego, United States
- Employees
- 11,370
- Founded
- 1989
- Chief executive
- Michael Farrell
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ResMedRMD | $33.69B | 34.0% | 21.8 | +19.45% |
| West Pharmaceutical ServicesWST | $29.01B | 22.9% | 46.7 | +38.61% |
| MedlineMDLN | $51.94B | 5.4% | 89.7 | +8.01% |
| Becton, DickinsonBDX | $59.39B | 15.7% | 43.1 | +51.77% |
| SolventumSOLV | $15.14B | 5.9% | 100.1 | +20.62% |
| Baxter InternationalBAX | $13.39B | 7.6% | — | +48.76% |
Same industry or related industries, similar size. Compare ResMed with its competitors · Full profile
